Table 1.
Patient demographics, dialysis vintage (dialysis months), dialysis adequacy (urea reduction ratio), nPNA, Stoke–Davies comorbidity score (Davies comorbidity), myocardial infarction (MI), coronary artery bypass graft surgery (CABG), coronary artery stenting (stent), peripheral vascular disease (PVD), aortic or iliac artery aneurysm or carotid artery stenosis (CVD), transient ischaemic attack (TIA), antihypertensive medications (BP meds) and psychological distress (distress thermometer)
| Variable | All patients | Not frail | Frail |
|---|---|---|---|
| Patients, n | 2089 | 1199 | 890 |
| Male, n (%) | 1256 (60.2) | 788 (65.7) | 468 (52.6)*** |
| Age (years), mean ± SD | 64.6 ± 16.6 | 59.1 ± 15.6 | 71.5 ± 12.3*** |
| White, n (%) | 898 (43.3) | 525 (25.3) | 373 (18) |
| Black, n (%) | 567 (27.4) | 337 (16.3) | 230 (11.5) |
| South Asian, n (%) | 453 (21.9) | 237 (11.4) | 216 (10.4)*** |
| East Asian, n (%) | 136 (6.6) | 93 (4.5) | 43 (2.1) |
| Weight (kg), mean ± SD | 70.6 ± 18.5 | 71.1 ±17.0 | 70.0 ± 20.1 |
| BMI (kg/m2), mean ± SD | 25.7 ± 6.0 | 25.5 ±5.4 | 26.0 ± 6.7*** |
| Dialysis (months), median (IQR) | 29.8 (12.2–65.3) | 26.1 (10.9–56.1) | 36.4 (13.7–72.8)*** |
| Urea reduction ratio (%), mean ± SD | 75.7 ± 9.5 | 76.0 ±9.4 | 75.4 ± 9.5 |
| nPNA (g/kg/day), median (IQR) | 1.14 (0.96–1.4) | 1.18 (1.01–1.44) | 1.1 (0.92–1.34)*** |
| Davies comorbidity, median (IQR) | 1 (1–2) | 1 (0–2) | 2 (1–3)*** |
| Diabetes mellitus, % | 44.3 | 34.3 | 58.6 *** |
| MI/CABG/stent, % | 15.6/8/9.6 | 13.7/5.6/7.9 | 20***/11***/12** |
| PVD/CVD, % | 9.8/3.7 | 7/2.8 | 13.5***/5** |
| TIA/stroke, % | 2.4/12.3 | 2.3/7.9 | 2.7/18.3*** |
| Prescribed BP meds, n (%) | 1295 (62.4) | 796 (66.6) | 499 (56.6)*** |
| BP meds (n), median (IQR) | 1 (0–1.25) | 1 (0–2) | 1(0–1)*** |
| Cancer/active cancer, % | 15.3/5.2 | 14.8/4.4 | 15.9/6.3 |
| Smoker/ex-smoker, % | 15.9/32 | 20/31.1 | 10.1***/33.2 |
| Distress thermometer, median (IQR) | 4 (1–5) | 3 (1–5) | 4 (1–6) |
**P < 0.01 and ***P < 0.001 non-frail versus frail.